NT-proBNP Peptide Levels at Hospital Discharge Predict Whether Heart Failure Patients Receive Optimal Medication Doses

Patients with a less than 30% reduction in NT-proBNP during hospitalization (ΔNT-proBNP < 30%) were discharged on significantly lower doses of guideline-directed medical therapy (GDMT) medications. This association was significant regardless of clinical characteristics or in-hospital management. The in-hospital NT-proBNP burden and trajectory, as markers of residual congestion, were directly associated with underutilization of recommended heart failure medications at discharge.

Prospective observational study of patients hospitalized for acute heart failure with reduced ejection fraction (HFrEF). NT-proBNP levels were measured at admission and discharge. The percentage change in NT-proBNP (ΔNT-proBNP) was calculated and used to stratify patients. Discharge medication doses of titratable GDMT medications were compared across NT-proBNP trajectory groups.

Residual congestion at hospital discharge is one of the strongest predictors of readmission and death in heart failure. Paradoxically, this study shows that the sickest patients — those with the most residual congestion — are discharged on the lowest doses of the medications proven to save their lives. Using NT-proBNP as a guide to treatment optimization before discharge could improve both medication use and patient outcomes.

NT-proBNP is one of the most widely used peptide biomarkers in cardiology, and its role continues to expand from diagnosis to treatment guidance. This study adds treatment optimization at discharge to its clinical utility. As heart failure management moves toward biomarker-guided therapy, NT-proBNP trajectories during hospitalization could become standard decision-making tools — not just for diagnosis, but for ensuring patients leave the hospital on the best possible medication regimen.

The abstract appears to be truncated and some statistical details are incomplete. The study design is observational, so it cannot determine whether lower NT-proBNP declines cause lower GDMT dosing or whether both reflect patient frailty and comorbidity burden. Specific sample sizes and complete outcome data are not available from the abstract. The study focused on HFrEF and may not apply to heart failure with preserved ejection fraction.